Hereditary Angioedema Market By Drug Class (C1 Esterase Inhibitors, Kallikrien Inhibitor, Selective Bradykinin B2 Receptor Antagonist), By Product Drugs (Phase Iii Drug, Phase Ii Drug (Qualitative Information) ) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025
Hereditary angioedema is a disorder that results in frequent attacks of pain and inflammation accompanied with the swelling of legs, intestinal tract, arms, face and airway tract. There are three types of hereditary angioedema, types I, II and III which are distinguished by the underlying causes and the levels of blood protein called C1 inhibitors. Phenotypic expression in hereditary angioedema varies widely even among family members, the frequency and severity of attacks are unpredictable giving an expression that similar symptoms arises in all types. Type III was initially thought to be prevalent only in women but incidences have occurred in males in the same affected families.
For the purpose of this study, the global hereditary angioedema market is studied in terms of drug classes, pipeline drugs and geography. The drug classes studied in the report include C1 esterase inhibitors (Berinert, Haegarda, Cinryze and Ruconest), kallikrein inhibitors (Kalbitor), selective bradykinin B2 receptor antagonist (Firazyr) and others. The current pipeline drugs for this market include Phase III drug DX-2930 and phase II drug BCX-7353. Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.
The geographic segmentation of the global hereditary angioedema market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The regions are also further sub-segmented on the basis of major countries:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East and Africa
- GCC
- Rest of Middle East and Africa
Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global hereditary angioedema market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global hereditary angioedema market. The key players profiled in this report are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd.
Based on drug class, the global hereditary angioedema market is categorized into
- C1 Esterase Inhibitors
- Berinert
- Haegarda
- Cinryze
- Ruconest
- Kallikrein Inhibitor
- Kalbitor
- Selective Bradykinin B2 Receptor Antagonist
- Firazyr
- Others
The hereditary angioedema market is driven by factors such as increasing expenditure in pharmaceutical and biotechnology R&D focusing on genetic rare diseases, rising public awareness and alliances between pharmaceutical giants and research institutes. In addition, increasing number of diagnostic centers and growing physician awareness regarding disease etiology will propel the market penetration of hereditary angioedema drugs. In 2016, C1 esterase inhibitors segment held the largest market share chiefly due to factors such as recent FDA approval of Berinert and Haegarda. Technological advancement in the drug delivery for e.g. Haegarda is the only medication available as a subcutaneous treatment option for hereditary angioedema. Kallikrien inhibitors will be the fastest growing segment throughout the forecast period 2017-2025. Factors contributing to the growth of this segment are increasing incidences in patients with angioedema anaphylactic shock and promising product pipeline consisting of selective kallikrien inhibitors and plasma kallikrien inhibitors resulting in immediate relief due to faster onset of action. The major players in hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, Teva Pharmaceutical Industries Ltd.
For the purpose of this study, the global hereditary angioedema market is categorized into the following regional and country specific markets:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Rest of Middle East and Africa
North America was observed to be the largest market for hereditary angioedema in the base year 2016. According to the US Hereditary Angioedema Association, in 2016, about 3,904 people suffered with hereditary angioedema. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of hereditary angioedema, presence of pharmaceutical giants such as BioCryst Pharmaceuticals, Inc., CSL Behring and existence of developed research and healthcare institutions. The market growth in Europe is mainly attributed to the rising prevalence of genetic rare diseases, increasing demand for novel drugs for the treatment of hereditary angioedema and affordable reimbursement scenario for the treatment of genetic rare diseases. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2017-2025. Factors that are anticipated to propel the market growth are the increasing disposable income and supportive regulatory environment for hereditary angioedema products. Moreover, factors such as developing health infrastructure, expansion by pharmaceutical giants in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of hereditary angioedema market in Latin America, and Middle East and Africa in the near future.
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Hereditary Angioedema Market Portraiture
2.1.1. Global Hereditary Angioedema Market, by Drug Class, 2016
2.1.2. Global Hereditary Angioedema Market, by Geography, 2016
Chapter 3. Hereditary Angioedema: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016
Chapter 4. Global Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Hereditary Angioedema Market, by Drug Class
4.3. C1 Esterase Inhibitors
4.3.1. Berinert
4.3.2. Haegarda
4.3.3. Cinryze
4.3.4. Ruconest
4.4. Kallikrien Inhibitor
4.4.1. Kalbitor
4.5. Selective Bradykinin B2 Receptor Antagonist
4.5.1. Firazyr
4.6. Others
Chapter 5. Global Hereditary Angioedema Market, by Product Drugs, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. Phase III Drug
5.2.1. DX-2930
5.3. Phase II Drug (Qualitative Information)
5.3.1. BCX-7353
Chapter 6. Global Hereditary Angioedema Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Hereditary Angioedema Market Analysis, 2015 – 2025
6.2.1. North America Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.2.2. North America Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe Hereditary Angioedema Market Analysis, 2015 – 2025
6.3.1. Europe Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.3.2. Europe Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. France
6.3.2.4. Rest of Europe
6.4. Asia Pacific Hereditary Angioedema Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. India
6.4.2.4. Rest of APAC
6.5. Latin America Hereditary Angioedema Market Analysis, 2015 – 2025
6.5.1. Latin America Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Hereditary Angioedema Market Analysis, 2015 – 2025
6.6.1. MEA Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.6.2. MEA Hereditary Angioedema Market, by Region, 2015 – 2025 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA
Chapter 7. Company Profiles
7.1. BioCryst Pharmaceuticals, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Cipla, Inc.
7.3. CSL Behring Ltd.
7.4. Ionis Pharmaceuticals, Inc.
7.5. iBio, Inc.
7.6. Merck & Co., Inc.
7.7. Pharming Group NV
7.8. Sanofi N.V.
7.9. Shire plc.
7.10. Teva Pharmaceutical Industries, Ltd.
7.11. Other Notable Players
TABLE 1 Global Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 2 Global Hereditary Angioedema Market, by Pipeline Drugs, 2015 – 2025 (US$ Mn)
TABLE 3 Global Hereditary Angioedema Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 North America Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Hereditary Angioedema Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 14 BioCryst Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Cipla, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 CSL Behring Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Ionis Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 iBio, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Pharming Group NV: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Sanofi N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Shire plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Teva Pharmaceutical Industries, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
FIG. 1 Hereditary Angioedema: Market Segmentation
FIG. 2 Global Hereditary Angioedema Market Share, by Drug Class, 2016 (Value %)
FIG. 3 Global Hereditary Angioedema Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global C1 Esterase Inhibitors Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Berinert Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Haegarda Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Cinryze Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Ruconest Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Kalbitor Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Firazyr Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Other Drug Class for Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 14 U.S. Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 15 Canada Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 16 U.K. Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 17 Germany Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 18 France Hereditary Angioedema Market, 2015-2025 (US$ Mn)
FIG. 19 Rest of Europe Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 20 Japan Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 21 China Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 22 India Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 23 Rest of Asia Pacific Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 24 Brazil Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 25 Mexico Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 26 Rest of Latin America Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 27 GCC Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 28 Rest of Middle East and Africa Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)